How to solve the specific manufacturing challenges associated with small molecules Active Pharmaceutical Ingredients (APIs)?
Drug discovery in oncology is accelerating and new therapeutic modalities have emerged during the last few years, allowing to address previously undruggable targets, and expanded the medical armamentarium against cancer.
While Biologics have concentrated expectations of new developments until recently in oncology, there is a record number of small molecules candidates in the clinical stage. These new small molecule drugs can reach targets that biologics may not access, and there are often associated with more complex chemistries. This new golden age requires more specific chemistry expertise and capabilities. Seqens has developed its capacities and invested in several large-scale assets for the manufacturing of anticancer Active Pharmaceutical Ingredients, with highly potent and potent capabilities.
Watch this webinar where SEQENS will present how to help solving the specific manufacturing challenges associated with the New Molecular Entities in development in oncology.
During this webinar you will learn:
- How to manage low Occupational Exposure Limits for the manufacturing of Potent active ingredients and intermediates
- Case studies on handling potent chemicals: from lab scale to process industrialization
- Insights on our new capacities for manufacturing anticancer Active Pharmaceutical Ingredients, with highly potent and potent capabilities
Speakers :
- Nathalie Argentin, Group Industrial Hygiene Expert
- Charles Guerin, Head of R&D Chemical Development – Innovative
- Charles Brigati, Process Engineer – Industrial Projects
- Ronan Rocle, Technology Marketing Manager
